Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

Panelists discuss how distinct safety profiles among Bruton tyrosine kinase (BTK) inhibitors—including variations in cardiovascular effects, bleeding risk, infection susceptibility, and other adverse events—guide personalized treatment decisions in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on individual comorbidities and risk factors.

EP: 1.Fixed-Duration Options for CLL

EP: 2.Pirtobrutinib in the BRUIN CLL-321 Study

EP: 3.Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

EP: 4.Sequencing Considerations in Relapsed/Refractory CLL

EP: 5.Selecting the Optimal BTK Inhibitor in Relapsed/Refractory CLL

Now Viewing

EP: 6.Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

EP: 7.The Inflation Reduction Act and Cost Considerations for BTK Inhibitors

EP: 8.Switching Between BTK Inhibitors in CLL

EP: 9.Discontinuing Versus Switching BTK Inhibitors for Toxicity

EP: 10.Opportunities for Easing BTK Inhibitor Switches

EP: 11.Reflections on 2024’s Progress in R/R CLL

Video content above is prompted by the following:

• How do differences in safety profiles between BTK inhibitors influence treatment selection in R/R CLL?

Related Videos

Related Content

Advertisement

Published: February 25th 2025 | Updated: February 25th 2025

Dry Eye Symptom Frequency, Severity Reduced When Using Perfluorohexyloctane

Julia Bonavitacola

Perfluorohexyloctane ophthalmic solution had high treatment satisfaction in those who took it for dry eye.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 24th 2025

Similar Chronic Condition Rates in MA, FFS Beneficiaries Raise Concerns About Overpayments to MA Plans

Brooke McCormick

These findings support the claim that Medicare Advantage (MA) payments may be driven more by diagnosis and coding practices rather than differences in disease burden between MA and fee-for-service (FFS) Medicare beneficiaries.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 21st 2025

AChR-Ab Titers Associated With Myasthenia Gravis Severity

Rose McNulty

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.

February 21st 2025

Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury

John K. Yue, MD Nishanth Krishnan, BS Christopher Toretsky, MPH Renee Y. Hsia, MD, MSc Geoffrey T. Manley, MD, PhD W. John Boscardin, PhD Anil N. Makam, MD, MAS Anthony M. DiGiorgio, DO, MHA

Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.

Related Content

Advertisement

Published: February 25th 2025 | Updated: February 25th 2025

Dry Eye Symptom Frequency, Severity Reduced When Using Perfluorohexyloctane

Julia Bonavitacola

Perfluorohexyloctane ophthalmic solution had high treatment satisfaction in those who took it for dry eye.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

February 24th 2025

Similar Chronic Condition Rates in MA, FFS Beneficiaries Raise Concerns About Overpayments to MA Plans

Brooke McCormick

These findings support the claim that Medicare Advantage (MA) payments may be driven more by diagnosis and coding practices rather than differences in disease burden between MA and fee-for-service (FFS) Medicare beneficiaries.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

February 21st 2025

AChR-Ab Titers Associated With Myasthenia Gravis Severity

Rose McNulty

Anti-acetylcholine receptor antibody (AChR-Ab) titers and the AChR-Ab rates of change correlated with myasthenia gravis disease severity scores in a recent study.

February 21st 2025

Insurance Payer Is Associated With Length of Stay After Traumatic Brain Injury

John K. Yue, MD Nishanth Krishnan, BS Christopher Toretsky, MPH Renee Y. Hsia, MD, MSc Geoffrey T. Manley, MD, PhD W. John Boscardin, PhD Anil N. Makam, MD, MAS Anthony M. DiGiorgio, DO, MHA

Among hospitalized patients with traumatic brain injury, Medicaid fee-for-service was associated with longer hospital stays than private insurance and Medicaid managed care organizations.